Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
3.170
+0.080 (2.59%)
Nov 28, 2025, 4:00 PM EST - Market closed
Absci Revenue
Absci had revenue of $378.00K in the quarter ending September 30, 2025, a decrease of -77.78%. This brings the company's revenue in the last twelve months to $2.82M, down -33.09% year-over-year. In the year 2024, Absci had annual revenue of $4.53M, down -20.71%.
Revenue (ttm)
$2.82M
Revenue Growth
-33.09%
P/S Ratio
144.18
Revenue / Employee
$17,930
Employees
157
Market Cap
476.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.53M | -1.18M | -20.71% |
| Dec 31, 2023 | 5.72M | -29.00K | -0.50% |
| Dec 31, 2022 | 5.75M | 965.00K | 20.18% |
| Dec 31, 2021 | 4.78M | 2.00K | 0.04% |
| Dec 31, 2020 | 4.78M | 2.72M | 132.04% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABSI News
- 6 days ago - Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 15 days ago - Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 16 days ago - Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results - GlobeNewsWire
- 4 weeks ago - Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025 - GlobeNewsWire
- 4 weeks ago - Absci to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial - GlobeNewsWire
- 2 months ago - Absci Boosts AI-Powered Drug Discovery With Oracle And AMD Collaboration - Benzinga
- 2 months ago - Absci Accelerates AI-Driven Drug Discovery with Oracle and AMD - GlobeNewsWire